IMVTEarnings•globenewswire•
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
Sentiment:Negative (20)
Summary
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for the quarter ended June 30, 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire